Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02127190 · ClinicalTrials.gov registry record · Phase 1

Study of CXA-10 in Healthy Volunteers

A Phase 1 study, sponsored by Complexa.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT02127190: Completed Phase 1 study, sponsored by Complexa.

NCT02127190 is a Phase 1 study that has completed, run by Complexa. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02127190, a Phase 1 study, has completed, sponsored by Complexa.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety and tolerability of the rate of the emulsion vehicle infusion in healthy volunteers. In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.

Interventions

  • DRUG Placebo
  • DRUG CXA-10 emulsion

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-04
Est. Completion 2014-12
Phase Phase 1
Complexa

8 total trials

What the finished NCT02127190 record still lists

NCT02127190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02127190 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02127190 about?

NCT02127190 is a clinical study titled "Study of CXA-10 in Healthy Volunteers". This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety and tolerability of the rate of the emulsion vehicle infusion in healthy ...

What is the current status of trial NCT02127190?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-04. Estimated completion is 2014-12.

What interventions are being tested in trial NCT02127190?

The interventions under investigation include: Placebo (DRUG), CXA-10 emulsion (DRUG).

Who is sponsoring clinical trial NCT02127190?

This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02127190's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02127190, the US trial registry maintained by the National Library of Medicine. NCT02127190 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.